Johnson & Johnson (JNJ)
| Market Cap | 374.14B |
| Revenue (ttm) | 87.70B |
| Net Income (ttm) | 14.68B |
| Shares Out | 2.41B |
| EPS (ttm) | 6.04 |
| PE Ratio | 25.72 |
| Forward PE | 15.39 |
| Dividend | $4.96 (3.19%) |
| Ex-Dividend Date | Nov 26, 2024 |
| Volume | 4,135,554 |
| Open | 154.63 |
| Previous Close | 154.52 |
| Day's Range | 154.60 - 156.63 |
| 52-Week Range | 143.13 - 168.85 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 175.64 (+13.02%) |
| Earnings Date | Jan 22, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, Johnson & Johnson's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $175.64, which is an increase of 13.02% from the latest price.
News
BMY Stock vs. JNJ Stock
Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forw...
Strategic ETF Allocations: Enhancing Income, Diversification, And Reducing Risks In Your Dividend Portfolio
I added shares of the Schwab U.S. Dividend Equity ETF and the Cohen & Steers Quality Income Realty Fund to The Dividend Income Accelerator Portfolio, boosting income and portfolio diversification. The...
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offe...
3 Dividend Kings So You Can Sleep Well At Night
Dividend Kings, like Coca-Cola, Johnson & Johnson, and Walmart, are prime long-term investments due to their consistent dividend growth over 50+ years. Coca-Cola offers a 3% yield and strong EBITDA gr...
Which Is A Better Pick: JNJ Stock Or AbbVie?
Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expec...
Of 63 Fortune 500 Industry Leaders, 57 Pay Dividends, 38 Are Cash Rich And 1 Is A Buy
AT&T, Altria Group, and Energy Transfer are top buys with dividends from $1K invested exceeding single share prices, meeting the dogcatcher ideal. Analysts forecast 15.47% to 28.33% net gains by Novem...
If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%
I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Both pay an attractive Dividend Yield [FWD] of 6.14% (Pfizer) and 6.58% (Verizon) and hav...
Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive
The Health Care sector faces uncertainty due to speculation about Robert F. Kennedy, Jr. leading HHS, impacting stocks like Johnson & Johnson. Despite solid earnings, JNJ shares have been under pressu...
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic mal...
J&J's skin disease drug meets main goals of late-stage study
Johnson & Johnson's drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psori...
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC-TOTAL achieved its primary endpoi...
Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conferen...
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wild...
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facili...
2 Of The Cheapest, High-Quality Dividend Stocks On The Market
In today's market, sticky inflation and elevated valuations make stock picking a challenge. But some dividend stocks still stand out as strong, long-term picks. These two dividend stocks offer growth ...
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant ...
Johnson & Johnson: Tracking Well Above The Industry
In the second half of 2024, Johnson & Johnson made significant progress in developing its oncology franchise. So, Darzalex sales were $3.02 billion in the third quarter of 2024, up 20.7% year-on-year,...
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the ...
Johnson & Johnson Enters Oversold Territory
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
67 Aristocrats November Dividend Cornucopia Has 39 'Safer' And 2 Ideal Dogs
November's top-yielding Aristocrats include Franklin Resources, Amcor, Hormel, and Kenvue, meeting the dogcatcher ideal of dividends from $1K invested exceeding single share prices. Analysts forecast ...
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
If approved, DARZALEX FASPRO ® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat bef...
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma
If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before th...
My Top 10 High Dividend Yield Companies For November 2024: 2 Yield More Than 8%
I will highlight 10 high dividend yield companies which, I believe, are worth considering investing in for November 2024. Each company could increase your portfolio's ability to generate dividend inco...